Spironolactone now has
the trial it was missing.

Spironolactone was developed in the 1950s as a potassium-sparing diuretic for treating hypertension and heart failure, and its anti-androgen effect was discovered as an off-target action. It blocks the binding of testosterone and dihydrotestosterone (DHT) to the androgen receptor, and at higher doses it reduces overall androgen synthesis. In women with hormonally driven acne, both effects contribute to a reduction in androgen-stimulated sebum production, the underlying driver that topical treatments cannot reach.

The reason this matters for hormonal acne specifically is that the deep, cyclical breakouts along the jawline, chin, and lower face that characterize this pattern are driven by sebum overproduction from androgen-sensitive sebaceous glands. Killing surface bacteria with benzoyl peroxide does nothing to change the underlying sebum environment. Dissolving keratin in pores with salicylic acid clears the symptom without addressing the cause. Tretinoin slows comedone formation but does not reduce sebum output. Spironolactone targets the actual upstream driver, which is why it succeeds where topicals plateau.

The catch is that spironolactone only works in this way for women. In men, the same mechanism would suppress testosterone systemically with predictable and unwanted consequences (gynecomastia, sexual side effects, fertility impacts). For this reason, spironolactone is not used for acne in men except in narrow specialist contexts. The evidence base, including the SAFA trial, is exclusively in adult female patients with persistent inflammatory acne, often with a hormonal pattern.

The strongest indicator that spironolactone will work is the clinical pattern itself: persistent inflammatory acne in adult women, located primarily on the lower face and jawline, often worsening in the week before menstruation, frequently with onset or recurrence in the twenties or thirties rather than the teens. This is what dermatologists call the "hormonal acne phenotype" and it overlaps substantially with conditions like polycystic ovary syndrome (PCOS), though most women with this acne pattern do not have a formal endocrine diagnosis.

The SAFA trial enrolled women with at least mild facial acne that had persisted for at least six months, and the responders mapped well to this phenotype. Women with predominantly comedonal acne, with adolescent-pattern T-zone acne, or without the cyclical pattern were less well-represented in the trial population, and clinical experience suggests they respond less reliably to spironolactone. The medication is best understood as a hormonal-pattern intervention rather than a general acne medication.

The timeline is what most patients underestimate. Spironolactone is slow. The SAFA trial showed early signal at 12 weeks but did not reach maximum improvement until week 24, six months. Most dermatologists report that 2 to 3 months at a stable dose is the minimum before judging whether the medication is working, with full effect at 4 to 6 months. This is fundamentally different from a topical that you can evaluate in 8 to 12 weeks. Patients who expect spironolactone to clear their skin in a month consistently get disappointed and quit before the medication has had a chance to work.

The SAFA trial used 50 mg daily for the first 6 weeks, increasing to 100 mg daily thereafter for patients who tolerated it. This dosing reflects current dermatology consensus, which generally starts at 25 to 50 mg and titrates up to 100 to 150 mg over 4 to 8 weeks based on response and tolerability. Doses above 200 mg are uncommon for acne and not better-supported by the evidence than 100 to 150 mg.

The most common side effects in the SAFA trial were mild and consistent with the medication's diuretic and anti-androgen effects: increased urination, breast tenderness, menstrual irregularity, and lightheadedness. Serious side effects were rare. Hyperkalemia (high potassium) is the laboratory finding to watch for, clinically significant only in patients with kidney disease or those taking other potassium-sparing medications. Routine potassium monitoring is debated; some dermatologists check baseline labs and one follow-up, others do not check in healthy young women.

Spironolactone is a confirmed teratogen, it can feminize a male fetus, which is why it is almost always co-prescribed with a reliable form of contraception in women of reproductive age. Combined oral contraceptives are the most common pairing, both for contraception and because they produce additive anti-androgen effects on acne. Stopping spironolactone often produces a rebound in acne over 2 to 6 months as androgen-driven sebum production returns, which is one reason patients who do well on it often stay on it for years rather than cycling on and off.

Because the timeline runs to six months, structured tracking is essential to evaluate spironolactone honestly. The brain is not reliable across this timescale, it anchors to recent events and underweights gradual change. Most women on spironolactone, three months in, do not have a clear sense of whether their skin is better than baseline because their memory of baseline has already faded. Photos and a daily severity log are what convert this from feel to data.

The right approach is two to four weeks of pre-treatment baseline, then a daily severity score, lesion count if practical, and a note on cycle phase for the duration of the trial. The signal you are looking for is a reduction in deep inflammatory lesions on the lower face, particularly in the week before menstruation, when hormonal acne typically peaks. Improvement in cyclical timing (less severe premenstrual flare) often appears before reduction in baseline severity. Both are evidence the medication is working.

ClearSkin includes cycle tracking specifically because hormonal acne evaluation requires it. A monthly pattern view that shows lesion severity by cycle day, before and after starting spironolactone, is the clearest way to demonstrate whether the medication is changing the pattern your body is producing. If the premenstrual peaks are flattening over four to six months, spironolactone is working. If they are unchanged at month four despite a stable dose, the medication is unlikely to be the right tool and a dermatologist conversation about alternatives, combined oral contraceptives, isotretinoin, or other approaches, is warranted.